Document is current
Any future updates will be listed below
-
Authors
Goldfarb, David S.
Modersitzki, Frank
Skaar, Jeffrey R.
Li, Olivia
Salem, Sandra
Chen, Jing Voon
-
Funding
Funding for this research was provided by:
Novo Nordisk
- License Information
-
More Information
Article History
Received: 23 August 2024
Accepted: 4 September 2025
First Online: 16 October 2025
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization-Good Clinical Practice guidelines. This study is non-interventional and is based on de-identified retrospective real-world claims data. Therefore, it is not considered human subject research and is exempt from IRB oversight.
: Not applicable.
: DSG: Consultant: Arbor Biotechnologies, Alnylam, Lilac Pharmaceuticals; Research: Novo Nordisk, Travere; Owner: Moonstone Nutrition, Inc. FM: Consultant: Halozyme.JRS: Employee of Trinity Life Sciences during the performance of this study and currently holds equity in Trinity Life Sciences; currently an employee of Novo Nordisk with stock/stock options. OL: Employee of Trinity Life Sciences. SS is an employee of Novo Nordisk and holds stock/stock options. JVC: Employee of Genesis Research Group, which received payment from Novo Nordisk to oversee this research.
